PMID- 25850623
OWN - NLM
STAT- MEDLINE
DCOM- 20160713
LR  - 20211203
IS  - 1873-5592 (Electronic)
IS  - 1389-4501 (Linking)
VI  - 16
IP  - 10
DP  - 2015
TI  - mTOR: A Novel Therapeutic Target for Diseases of Multiple Systems.
PG  - 1107-32
AB  - Significant progress in the research of mammalian target of rapamycin (mTOR) in 
      recent years, has greatly enhanced our understanding of the role and cellular 
      pathways through which mTOR control cellular processes, such as translational 
      initiation, actin organization, cell proliferation, and cell survival. mTOR is 
      activated by phosphorylation and functions mainly through mTOR complex 1 or mTOR 
      complex 2. mTORC1 is activated through tuberous sclerosis complex 1/2 dependent 
      and independent mechanisms following the stimulation by growth factors, nutrient, 
      amino acids, and other signaling pathways. The activity of mTOR is closely 
      associated with cell proliferation and differentiation, apoptosis, and autophagy. 
      Activation of mTOR prevents the induction of both apoptosis and autophagy through 
      regulating its multiple targets. Given that the activity of mTOR has been 
      involved in the pathogenesis of neurodegenerative disorders, cardiovascular 
      abnormalities, metabolic diseases, renal transplantation, autoimmune 
      abnormalities, and cancer, manipulating mTOR activation may represent as an 
      innovative therapeutic strategy for these diseases. Yet, the role of mTOR in the 
      body is complicated and therefore, its activity needs to be tightly regulated to 
      achieve beneficial outcome in a specific pathological condition.
FAU - Chong, Zhao Zhong
AU  - Chong ZZ
AD  - Department of Anesthesiology, University of Illinois at Chicago, Chicago, IL, 
      USA. zzchong@uic.edu.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Drug Targets
JT  - Current drug targets
JID - 100960531
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - Apoptosis/drug effects
MH  - Cardiovascular Diseases/*metabolism/pathology/therapy
MH  - Cell Cycle/drug effects
MH  - Cell Proliferation/drug effects
MH  - Diabetes Mellitus/*metabolism/pathology/therapy
MH  - Humans
MH  - Molecular Targeted Therapy/*methods
MH  - Neoplasms/*metabolism/pathology/therapy
MH  - Neurodegenerative Diseases/*metabolism/pathology/therapy
MH  - Phosphorylation
MH  - TOR Serine-Threonine Kinases/genetics/*metabolism
EDAT- 2015/04/09 06:00
MHDA- 2016/07/14 06:00
CRDT- 2015/04/09 06:00
PHST- 2014/04/10 00:00 [received]
PHST- 2015/03/18 00:00 [revised]
PHST- 2015/03/30 00:00 [accepted]
PHST- 2015/04/09 06:00 [entrez]
PHST- 2015/04/09 06:00 [pubmed]
PHST- 2016/07/14 06:00 [medline]
AID - CDT-EPUB-66401 [pii]
AID - 10.2174/1389450116666150408103448 [doi]
PST - ppublish
SO  - Curr Drug Targets. 2015;16(10):1107-32. doi: 10.2174/1389450116666150408103448.